by Julia Foresman | Featured Article, Latest News
Anti-allergy EpiPen manufacturer Mylan NV faces new scrutiny as lawmakers react to the outcry from last month’s price hike disclosure. Specifically, this week U.S. legislators called for a probe of Mylan’s company rebates to government healthcare plans, Medicare and...
by Julia Foresman | Big Deals, Featured Article, Latest News
EY released their annual Firepower Index and Growth Gap Report last week, revealing a hotbed of lucrative M&A activity in the biopharmaceutical industry. Deal activity for 2015 exceeded 300 billion (USD) as companies scrambled to address growth gaps and fine tune...